FURIN and viral infectious disease: The non-toxic BOS furin inhibitor, when used in conjunction with a TMPRSS2 inhibitor, significantly reduced viral entry into lung cells, achieving an approximate 95% reduction in viral infection—a promising approach for combating the spread of SARS-CoV-2, including Omicron variants [29,31].